{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:54:28Z","timestamp":1792803268730,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807153604010"],"award-info":[{"award-number":["JCYJ20230807153604010"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijantimicag.2026.107789","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:34:06Z","timestamp":1774283646000},"page":"107789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance"],"prefix":"10.1016","volume":"67","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Takiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-3672","authenticated-orcid":false,"given":"Qian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107789_bib0001","series-title":"Global tuberculosis report 2024","year":"2024"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/0003-4819-149-2-200807150-00008","article-title":"Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis","volume":"149","author":"Lew","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0003","series-title":"Tuberculosis profile: global","year":"2024"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","author":"Goodall","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0005","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0006","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMc2404644","article-title":"Transmission as a key driver of resistance to the new tuberculosis drugs","volume":"392","author":"Goig","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0008","series-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","year":"2023"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0009","series-title":"Target product profile for tuberculosis diagnosis and detection of drug resistance","year":"2024"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0010","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Hopewell","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824","volume":"2","author":"Manjunatha","year":"2009","journal-title":"Communicat Integrat Biol"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0012","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0013","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.str.2011.11.001","article-title":"Structure of ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824","volume":"20","author":"Cellitti Susan","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0014","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01948-20","article-title":"Mutations in fbiD (Rv2983) as a novel determinant of resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis","volume":"65","author":"Rifat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0016","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02141-18","article-title":"Clofazimine exposure In Vitro selects efflux pump mutants and bedaquiline resistance","volume":"63","author":"Ismail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0018","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/IDR.S257145","article-title":"Genetic and virulence characteristics of linezolid and pretomanid dual drug-resistant strains induced from Mycobacterium tuberculosis in vitro","volume":"13","author":"Hu","year":"2020","journal-title":"Infection And Drug Resistance"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0019","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00308-15","article-title":"Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous In vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis","volume":"59","author":"Haver","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tube.2017.12.006","article-title":"Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis","volume":"108","author":"Fujiwara","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00531-22","article-title":"Spontaneous mutational patterns and novel mutations for Delamanid resistance in Mycobacterium tuberculosis","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0022","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/AAC.03014-15","article-title":"MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration","volume":"60","author":"Stinson","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0023","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0024","first-page":"Unit 10A 2","article-title":"Genetic manipulation of Mycobacterium tuberculosis","volume":"10","author":"Larsen","year":"2007","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0025","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/infdis\/jiab011","article-title":"Lesion heterogeneity and long-term heteroresistance in multidrug-resistant tuberculosis","volume":"224","author":"Chen","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0026","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/ph17081068","article-title":"In vitro resistance-predicting studies and In vitro resistance-related parameters-a hit-to-lead perspective","volume":"17","author":"Krajewska","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00292-19","article-title":"In vitro study of stepwise acquisition of rv0678 and atpE mutations conferring Bedaquiline resistance","volume":"63","author":"Ismail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ng.1034","article-title":"Evolutionary paths to antibiotic resistance under dynamically sustained drug selection","volume":"44","author":"Toprak","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36955-y","article-title":"Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678","volume":"13","author":"Snobre","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0030","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.01611-09","article-title":"Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor","volume":"54","author":"Huitric","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0031","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41467-017-00721-2","article-title":"A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide","volume":"8","author":"Yadon","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0032","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00070-19","article-title":"Genomewide assessment of Mycobacterium tuberculosis conditionally essential metabolic pathways","volume":"4","author":"Minato","year":"2019","journal-title":"MSYSTEMS"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0034","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1021\/jm801374t","article-title":"Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships","volume":"52","author":"Kim","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008287","article-title":"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Path"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107789_bib0036","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2178243","article-title":"Designing molecular diagnostics for current tuberculosis drug regimens","volume":"12","author":"Georghiou","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98862-4","article-title":"Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid","volume":"11","author":"G\u00f3mez-Gonz\u00e1lez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00070-24","article-title":"Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid","volume":"12","author":"Rupasinghe","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2026.107789_bib0039","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/jac\/dkac070","article-title":"Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid","volume":"77","author":"Bateson","year":"2022","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T19:04:12Z","timestamp":1779735852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0924857926000786"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107789","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107789"}}